Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition …
LE Markowitz, S Hariri, C Lin, EF Dunne… - The Journal of …, 2013 - academic.oup.com
LE Markowitz, S Hariri, C Lin, EF Dunne, M Steinau, G McQuillan, ER Unger
The Journal of infectious diseases, 2013•academic.oup.comBackground. Human papillomavirus (HPV) vaccination was introduced into the routine
immunization schedule in the United States in late 2006 for females aged 11 or 12 years,
with catch-up vaccination recommended for those aged 13–26 years. In 2010, 3-dose
vaccine coverage was only 32% among 13–17 year-olds. Reduction in the prevalence of
HPV types targeted by the quadrivalent vaccine (HPV-6,-11,-16, and-18) will be one of the
first measures of vaccine impact. Methods. We analyzed HPV prevalence data from the …
immunization schedule in the United States in late 2006 for females aged 11 or 12 years,
with catch-up vaccination recommended for those aged 13–26 years. In 2010, 3-dose
vaccine coverage was only 32% among 13–17 year-olds. Reduction in the prevalence of
HPV types targeted by the quadrivalent vaccine (HPV-6,-11,-16, and-18) will be one of the
first measures of vaccine impact. Methods. We analyzed HPV prevalence data from the …
Abstract
Background. Human papillomavirus (HPV) vaccination was introduced into the routine immunization schedule in the United States in late 2006 for females aged 11 or 12 years, with catch-up vaccination recommended for those aged 13–26 years. In 2010, 3-dose vaccine coverage was only 32% among 13–17 year-olds. Reduction in the prevalence of HPV types targeted by the quadrivalent vaccine (HPV-6, -11, -16, and -18) will be one of the first measures of vaccine impact.
Methods. We analyzed HPV prevalence data from the vaccine era (2007–2010) and the prevaccine era (2003–2006) that were collected during National Health and Nutrition Examination Surveys. HPV prevalence was determined by the Linear Array HPV Assay in cervicovaginal swab samples from females aged 14–59 years; 4150 provided samples in 2003–2006, and 4253 provided samples in 2007–2010.
Results. Among females aged 14–19 years, the vaccine-type HPV prevalence (HPV-6, -11, -16, or -18) decreased from 11.5% (95% confidence interval [CI], 9.2–14.4) in 2003–2006 to 5.1% (95% CI, 3.8–6.6) in 2007–2010, a decline of 56% (95% CI, 38–69). Among other age groups, the prevalence did not differ significantly between the 2 time periods (P > .05). The vaccine effectiveness of at least 1 dose was 82% (95% CI, 53–93).
Conclusions. Within 4 years of vaccine introduction, the vaccine-type HPV prevalence decreased among females aged 14–19 years despite low vaccine uptake. The estimated vaccine effectiveness was high.
Oxford University Press